Infiltrating duct carcinoma of female breast
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
For in vivo antitumor studies, the tumor growth rate of mice treated with DTX-loaded <sup>D</sup>T7-LIP was significantly inhibited compared to that in mice treated with DTX-loaded <sup>L</sup>T7-LIP and DTX-loaded Tf-LIP.
|
30395963 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, these findings illustrate that SMG-1 is suppressed by miR-192 and-215 and functions as a tumor suppressor in GC by inactivating Wnt signaling and suppressing EMT.
|
29239144 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In vitro studies show that low oxygen increases hepatocellular ATX expression and transcriptome analysis showed a positive correlation between ATX mRNA levels and hypoxia gene score in HCC tumour tissue associated with HCV and other aetiologies.
|
28126468 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Knock down of the expression of SMG-1 inhibited tumor cell proliferation and induced the chemosensitivity of pancreatic cancer cells in vitro.
|
25760059 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, our results indicate that SMG1 acts as a potential tumor suppressor with epigenetic regulation in AML.
|
25257528 |
2014 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Further study showed that SMG-1 expression was exactly associated with tumor differentiation and clinical stage in HCC.
|
24700316 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Given an increased tumor growth following depletion of SMG-1, our data demonstrate a novel role for SMG-1 in regulating Cdc25A and suppressing oncogenic CDK2 driven proliferation, confirming SMG-1 as a tumor suppressor.
|
24107632 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An important player in the DDR, SMG-1 (suppressor with morphogenetic effect on genitalia), is a potential tumor suppressor and may therefore be deregulated in cancer.
|
22247495 |
2012 |
Lymphocyte Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
The combination of a genome-wide association study of lymphocyte count and analysis of gene expression data reveals novel asthma candidate genes.
|
22286170 |
2012 |
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study identifies five new schizophrenia loci.
|
21926974 |
2011 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Autotaxin (ATX/NPP2) is a tumor cell motility-stimulating factor that displays both a nucleotide pyrophosphatase/phosphodiesterase activity and a recently described lysophospholipase D (lysoPLD) activity.
|
15027116 |
2004 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although the inter-patient variability was large, we found that LIP, the isoform of C/EBPbeta known to inhibit transcription, was expressed at higher levels in Duke's stage B tumors compared with Duke's stage A, whereas Duke's C tumors had the lowest LIP expression.
|
10760820 |
2000 |
Malignant Neoplasms
|
0.070 |
GeneticVariation
|
group |
BEFREE |
In mice, total loss of SMG1 is embryonic lethal and loss of a single allele results in an increased rate of cancer development, particularly haematopoietic cancers and lung cancer.
|
31565865 |
2019 |
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Recent accumulating evidence indicates the biological actions of Autotaxin-Lysophosphatidic acid (ATX-LPA) signaling axis in malignant tumors.
|
30921203 |
2019 |
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
ATX is a novel player in the pathogenesis of liver fibrosis and cancer and a promising therapeutic target.(Hepatology 2017;65:1369-1383).
|
27981605 |
2017 |
Malignant Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Here, we report for the first time, that the truncated CCAAT-enhancer-binding protein β (C/EBPβ) LIP isoform is abnormally overexpressed and correlated with cancer metastasis in clinical specimens of human ESCC.
|
24994936 |
2014 |
Malignant Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
No studies have yet been conducted linking defects in SMG-1 expression with cancer.
|
22247495 |
2012 |
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
In the present article, we review some of the key findings that make the ATX-LPA signalling axis an emerging target for cancer therapy.
|
22260662 |
2012 |
Malignant Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
The transcription factor C/EBPbeta may be involved in malignancy with its alternative translation product C/EBPbeta-LIP.
|
19958352 |
2010 |
Primary malignant neoplasm
|
0.060 |
GeneticVariation
|
group |
BEFREE |
In mice, total loss of SMG1 is embryonic lethal and loss of a single allele results in an increased rate of cancer development, particularly haematopoietic cancers and lung cancer.
|
31565865 |
2019 |
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
ATX is a novel player in the pathogenesis of liver fibrosis and cancer and a promising therapeutic target.(Hepatology 2017;65:1369-1383).
|
27981605 |
2017 |
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Here, we report for the first time, that the truncated CCAAT-enhancer-binding protein β (C/EBPβ) LIP isoform is abnormally overexpressed and correlated with cancer metastasis in clinical specimens of human ESCC.
|
24994936 |
2014 |
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
No studies have yet been conducted linking defects in SMG-1 expression with cancer.
|
22247495 |
2012 |
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
In the present article, we review some of the key findings that make the ATX-LPA signalling axis an emerging target for cancer therapy.
|
22260662 |
2012 |